Perhaps some disappointment around the EBITDA guidance, but the results commentary did suggest a stronger than expected NPAT in H2 2024 due to cost cutting. I guess the proof will be in the pudding. Initially I was pleased by the ex covid testing revenue growth (even accounting for acquisitions), but looking at the even stronger growth in costs, this put a bit of a dampener on it. As you said, no franking credit on dividend.
Perhaps some disappointment around the EBITDA guidance, but the...
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$26.95 |
Change
-0.210(0.77%) |
Mkt cap ! $13.04B | |||
| Open | High | Low | Value | Volume |
| $27.20 | $27.29 | $26.90 | $717.3K | 26.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 303 | $26.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $26.98 | 108 | 4 |
View Market Depth
| Last trade - 10.42am 07/10/2024 (20 minute delay) ? |
| SHL (ASX) Chart |